亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

医学 促甲状腺激素受体 美罗华 免疫学 单克隆抗体 免疫疗法 内科学 格雷夫斯病 癌症研究 内分泌学 抗体 免疫系统 甲状腺
作者
Alan Chun Hong Lee,George J. Kahaly
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:16: 1571427-1571427 被引量:3
标识
DOI:10.3389/fimmu.2025.1571427
摘要

Background Graves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact. Current standard treatments have limitations regarding efficacy and safety, and most do not specifically target the pathogenic mechanisms. We aim to review the latest development of targeted immunotherapies in these two closely related disorders. Summary Targeted immunotherapies of Graves’ hyperthyroidism have recently demonstrated clinical efficacy in early phase clinical studies. They include rituximab, an anti-CD20 monoclonal antibody which causes rapid B cell depletion; ATX-GD-59, an antigen specific immunotherapy which restores immune tolerance to thyrotropin receptor; iscalimab, an anti-CD40 monoclonal antibody which blocks the CD40-CD154 co-stimulatory pathway in B-T cell interaction; and K1-70, a thyrotropin receptor blocking monoclonal antibody. Furthermore, there have been major therapeutic advances in the management of Graves’ orbitopathy. Mycophenolate has a dual mechanism of action both inhibiting the proliferation of activated B & T cells as well as the mammalian target of rapamycin growth intracellular pathway. Rituximab appears to be effective in active disease of recent onset without impending dysthyroid optic neuropathy. Both tocilizumab (anti-interleukin 6 receptor monoclonal antibody) and sirolimus (mammalian target of rapamycin inhibitor) showed promise in glucocorticoid resistant active disease. Teprotumumab, an anti-insulin-like growth factor-1 receptor monoclonal antibody, demonstrated remarkable all-round efficacy across a wide disease spectrum. Linsitinib, a dual small molecule inhibitor of insulin-like growth factor-1 receptor and insulin receptor, displayed significant proptosis reduction in its phase 2b/3 study. Finally, Batoclimab, an anti-neonatal fragment crystallizable receptor monoclonal antibody, which blocks recycling of pathogenic thyrotropin receptor antibody, showed promising signals for significant proptosis reduction, disease inactivation, overall response, and improvement of quality of life. Conclusion Therapeutic advances will continue to optimize our management of Graves’ hyperthyroidism and its associated orbitopathy in an effective and safe manner.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
李梦瑶完成签到 ,获得积分10
3秒前
动听的天宇完成签到,获得积分10
3秒前
香蕉觅云的应助被多情嫣然采纳,获得10
4秒前
6秒前
sweety01233完成签到,获得积分10
6秒前
6秒前
6秒前
Fury完成签到 ,获得积分10
8秒前
YZYJLS完成签到,获得积分10
10秒前
辛勤元芹关注了科研通微信公众号
11秒前
11秒前
阿腾发布了新的文献求助10
12秒前
陈锦洛完成签到 ,获得积分10
13秒前
15秒前
科研通AI65的应助被阿腾采纳,获得10
18秒前
肖肖关注了科研通微信公众号
19秒前
20秒前
21秒前
开朗的千雁完成签到 ,获得积分10
22秒前
weako发布了新的文献求助10
23秒前
斯文败类的应助被开心的中心采纳,获得10
24秒前
369ninja发布了新的文献求助10
27秒前
辛勤元芹发布了新的文献求助10
27秒前
hgl完成签到,获得积分10
27秒前
stooyan的应助被王星晓采纳,获得100
28秒前
28秒前
wanci的应助被Clearday采纳,获得10
29秒前
29秒前
自由滑大王完成签到 ,获得积分10
33秒前
酷炫如曼完成签到,获得积分10
34秒前
烨无殇完成签到,获得积分10
34秒前
Anla完成签到,获得积分10
38秒前
40秒前
41秒前
agnway完成签到,获得积分10
43秒前
搞怪的老九的应助被涵泽采纳,获得10
43秒前
lidocaine完成签到 ,获得积分10
44秒前
para完成签到,获得积分10
46秒前
肖肖发布了新的文献求助10
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778